Futura Medical Full Year 2024 Earnings: Beats Expectations

Futura Medical (LON:FUM) Full Year 2024 Results

Key Financial Results

• Revenue: UK£13.9m (up 349% from FY 2023).
• Net income: UK£1.29m (up from UK£6.51m loss in FY 2023).
• Profit margin: 9.3% (up from net loss in FY 2023). The move to profitability was driven by higher revenue.
• EPS: UK£0.004 (up from UK£0.022 loss in FY 2023).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Futura Medical Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) also surpassed analyst estimates by 141%.

The primary driver behind last 12 months revenue was the United States of America segment contributing a total revenue of UK£7.84m (56% of total revenue). The largest operating expense was General & Administrative costs, amounting to UK£6.83m (81% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of UK£49.1k. Explore how FUM's revenue and expenses shape its earnings.

Looking ahead, revenue is expected to decline by 29% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the United Kingdom are expected to grow by 5.0%.

Performance of the British Pharmaceuticals industry.

The company's shares are up 3.3% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for Futura Medical (1 is potentially serious!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.